Skip to main content

Announcements

9/2019Recall: Relpax 40 mg Tablets
Relpax is manufactured by Pfizer Inc. Two lot numbers of this medication have been recalled for safety reasons. This recall is due to the possible presence of bacteria. To date, Pfizer Inc. has not received any customer complaints or reports of adverse events related to this issue. Read the full text of the recall.
8/2019Recall: Drospirenone and Ethinyl Estradiol Tablets, USP
Jubilant Cadista Pharmaceuticals Inc. is recalling one lot of Drospirenone and Ethinyl Estradiol Tablets, USP, 3 mg/ 0.02mg due to concern that the medication will not work as well as it should. This is based on lab test results on how the medication is absorbed into the body. To date, Jubilant Cadista Pharmaceuticals Inc. has not received any reports of adverse events. Read the full text of the recall.
7/2019UPMC Health Plan would like to announce the new Hip and Knee Joint Replacement Centers of Excellence
UPMC Health Plan has established a Center of Excellence program for elective hip and knee joint replacement surgery to promote high-quality outcomes for members. The UPMC Health Plan Hip and Knee Joint Replacement Surgery Center of Excellence program recognizes surgical facilities and orthopedic surgeons that demonstrate high-quality outcomes, low complication rates, and the best patient experience for UPMC Health Plan members in need of joint replacement surgery. More information is available at upmchp.us/hip-knee-coe.
6/2019Recall: Losartan Potassium Tablets, USP
The FDA advises that patients who are on Losartan Potassium Tablets and Losartan Potassium/Hydrochlorothiazide combination tablets, USP should continue taking their medication and contact their pharmacist, physician, or medical provider for advice regarding an alternative treatment, as the risk of harm to the patient’s health may be higher if the treatment is stopped immediately without any alternative treatment. Read the full text of the recall.
6/2019Recall: Fentanyl
Heritage Pharmaceuticals Inc. is recalling lot #VEAC025 of Amikacin Sulfate Injection, USP, 1g/4 mL (250mg/mL) and lot #VPCA172 of Prochlorperazine Edisylate Injection, USP, 10mg/2mL (5mg/mL). This recall was issued because microbial growth was detected in unreleased medication. Read the full text of the recall.
6/2019Recall: Fentanyl
Alvogen Inc. is recalling two lots of Fentanyl Transdermal System 12 mcg/h transdermal patches because of mislabeling. A small number of cartons labeled 12 mcg/h Fentanyl Transdermal System patches contained 50 mcg/h patches. Read the full text of the recall.
5/2019EPSDT changes now in effect
Please note that changes have been made to the Early and Periodic Screening, Diagnosis, and Treatment (EPSDT) Periodicity Schedule. These changes were made in response to the Department of Human Services (DHS) Medical Assistance Bulletins released on August 1, 2018, and are relevant to all Medical Assistance providers. View the updated EPSDT Periodicity Schedule and UPMC for You billing guide.
5/2019Recall: Losartan Potassium Tablets, USP
Based on the available information, the risk of developing cancer following long-term use of the product containing high levels of the impurity NMBA cannot be ruled out. The FDA advises that Consumers should contact their doctor for further guidance and potential change of treatment before they stop taking the product. Read the full text of the recall.
4/2019Recall: Valsartan and Amlodipine/Valsartan
Aurobindo Pharma USA Inc. is recalling 39 lots of Valsartan and Amlodipine/Valsartan tablets because of an impurity found in the product. The impurity—N-nitrosodiethylamine (NDEA)—is classified as a probable human carcinogen. Read the full text of the recall.
4/2019Recall: Losartan Potassium Tablets, USP
Legacy Pharmaceutical Packaging, LLC is recalling 3 repackaged lots of Losartan Potassium Tablets, USP, 50 mg. This recall was prompted due to Torrent Pharmaceuticals LTD issuing a voluntary nationwide recall of Losartan Tablets, USP, because of an impurity found in the product. Read the full text of the recall.
4/2019Recall: Losartan Potassium Tablets, USP
Legacy Pharmaceutical Packaging, LLC is recalling 40 repackaged lots of Losartan Potassium Tablets, USP, 25 mg, 50 mg, and 100 mg. This recall was prompted due to Camber Pharmaceuticals, Inc. issuing a voluntary nationwide recall of Losartan Tablets, USP, because of an impurity found in the product. Read the full text of the recall.
3/2019Recall: Losartan/Hydrochlorothiazide (Macleods)
Macleods Pharmaceuticals Limited is recalling one lot number of Losartan/Hydrochlorothiazide because of an impurity found in the product. The impurity—N-nitrosodiethylamine (NDEA)—is classified as a probable human carcinogen. Read the full text of the recall.
3/2019Recall: Irbesartan and Irbesartan/Hydrochlorothiazide
Prinston Pharmaceutical Inc., dba Solco Healthcare LLC, is recalling 1 lot of Irbesartan and 7 lots of Irbesartan/Hydrochlorothiazide because of an impurity found in the product. The impurity—N-nitrosodiethylamine (NDEA)—is classified as a probable human carcinogen. Read the full text of the recall.
3/2019Recall: Losartan and Losartan/HCTZ (Torrent)
Torrent Pharmaceuticals Limited is recalling 10 lot numbers of Losartan and 6 lot numbers of Losartan/Hydrochlorothiazide because of an impurity found in the product. The impurity—N-nitrosodiethylamine (NDEA)—is classified as a probable human carcinogen. Read the full text of the recall.
1/2019Recall: Valsartan
Aurobindo Pharma USA Inc. is recalling 80 lots of Valsartan, Amlodipine and Valsartan, and Valsartan and Hydrochlorothiazide because of an impurity found in the product. Read the full text of the recall.
1/2019Recall: Losartan (Torrent)
Torrent Pharmaceuticals Limited is recalling 10 lot numbers of Losartan because of an impurity found in the product. The impurity—N-nitrosodiethylamine (NDEA)—is classified as a probable human carcinogen. Read the full text of the recall.

Expand All Collapse All

2018 Announcements

12/2018Recall: Infant Ibuprofen
Tris Pharma Inc. is recalling three lots of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL. The recalled lots have been found to potentially contain higher concentrations of ibuprofen. No problems linked to this recall have been reported. Read the full text of the recall.
12/2018Recall: Sodium Chloride Injection .09%
Fresenius Kabi USA is recalling 163 lots of Sodium Chloride Injection 0.9% vials because of mislabeling. The product insert states that stoppers for both the 10 ml and 20 ml vials do not contain rubber latex. However, the product is being recalled because the stoppers have been found to contain natural rubber latex. Read the full text of the recall.
12/2018Recall: Losartan HCTZ
Mylan Pharmaceuticals is recalling select lot numbers of Valsartan, Amlodipine and Valsartan, and Valsartan and Hydrochlorothiazide because of an impurity found in the product. The impurity—N-nitrosodiethylamine (NDEA)—is classified as a probable human carcinogen. Read the full text of the recall.
11/2018Recall: Losartan HCTZ
Sandoz Inc. is recalling lot number JB8912 of Losartan Hydrochlorothiazide because of an impurity found in the drug product. No problems linked to this recall have been reported so far. Read the full text of the recall.
11/2018Recall: Ortho-Novum
Janssen Pharmaceuticals Inc. is recalling several lots of Ortho-Novum 7/7/7 and 1/35 tablets because the patient information provided inside affected packages does not include the appropriate instructions for the dispenser. The Ortho-Novum product itself remains safe and effective for use with the appropriate dispenser instructions. Read the full text of the recall.
11/2018Recall: Ibesartan
ScieGen Pharmaceuticals is voluntarily recalling all unexpired lots of Irbesartan because of an impurity found in the product. Companies affected by this recall include Golden State Medical Supply Inc. (GSMS) and Westminster Pharmaceuticals. Read the full text of the recall.
8/2018Recall: Valsartan and Valsartan/Hydrochlorothiazide (HCTZ)
Solco Healthcare, Teva Pharmaceuticals Industry Ltd., Major Pharmaceuticals, Camber Pharmaceuticals, Northwind Pharmaceuticals, and several repackaging manufacturers are voluntarily recalling all unexpired lots of Valsartan and Valsartan/Hydrochlorothiazide because of an impurity found in the product. Read the full text of the recall.
8/2018Recall: Levothyroxine or Liothyronine (Thyroid Tablets)
Westminster Pharmaceuticals, LLC is voluntarily recalling all unexpired lot numbers of Levothyroxine and Liothyronine (Thyroid Tablets, USP) 15 mg, 30 mg, 60 mg, 90 mg, and 120 mg. These products are being recalled as a precaution because they were manufactured using active pharmaceutical ingredients sourced prior to a 2017 inspection that found one supplier to have deficiencies with Current Good Manufacturing Practices (cGMP). Read the full text of the recall.
8/2018Recall: Valsartan and Valsartan/Hydrochlorothiazide
Solco Healthcare, Teva Pharmaceuticals Industry Ltd., and Major Pharmaceuticals are voluntarily recalling all unexpired lots of Valsartan and Valsartan/Hydrochlorothiazide because of an impurity found in the product. Read the full text of the recall.
6/2018Provider Manual Update
The UPMC for You (Medical Assistance) chapter of the UPMC Health Plan Provider Manual has been updated with an effective date of July 1, 2018. To view the most recent changes, visit our Provider Manual page.
6/2018Recall: Fluticasone Propionate Nasal Spray
Apotex Corp. is voluntarily recalling one lot of Fluticasone Propionate Nasal Spray due to containing small glass particles. Read the full text of the recall.
6/2018Recall: Naloxone Hydrochloride Injection
Hospira Inc. is voluntarily recalling two lots of Naloxone Hydrochloride Injection because of the potential presence of embedded and loose particulate matter on the syringe plunger. Read the full text of the recall.
5/2018Recall: Ampicillin and Sulbactam for Injection
AuroMedics Pharma LLC is voluntarily recalling two lots of Ampicillin and Sulbactam for Injection because customers noticed red particulate matter in the product. Read the full text of the recall.
3/2018Recall: Methylprednisolone Sodium Succinate for Injection
Sagent Pharmaceuticals Ltd. has initiated this voluntary recall of Methylprednisolone Sodium Succinate for Injection, USP to the user level due to the discovery of high out-of-specification impurity results. Read the full text of the recall.
3/2018 Alcohol Use and Alcohol Problems Event
We want to help you, help your patients. UPMC Health Plan is hosting an event to discuss and share resources that help your patients and their families cope with an alcohol problem. Learn more about the event.
2/2018 Reminder: Update PROMISe IDs
Effective January 1, 2018, UPMC for You Medicaid, UPMC for Kids CHIP, and UPMC for Life Dual Medicare SNP providers must have updated PROMISe ID numbers to render, order/refer, or prescribe items or services to patients covered under those plans. If you do not have a PROMISe ID, claims will be denied.
Don’t wait — enroll online now!
2/2018 Align yourself with thought leaders
Our leaders are applying their expertise, along with creativity and rigor, to some of the most challenging problems in health care delivery and financing. Our latest research findings can give you a unique perspective and new ideas on current topics.
To review the latest thought leadership lineup, please visit http://upmchp.us/research.
1/2018 Obstetrical Needs Assessment (OBNA) form submission
Please submit the obstetrical needs assessment form (OBNA) electronically via Optum OB Care or EPIC. Provider offices without capability for EPIC submission should use Optum OB Care. Faxed copies will not be accepted.
1/2018 Recall: Clopidogrel 75 mg tablets
International Laboratories, LLC is voluntarily recalling Lot# 117099A of Clopidogrel tablets, USP 75 mg, packaged in bottles of 30 tablets, to the consumer level due to mislabeling. The product is labeled as Clopidogrel tablets USP 75 mg but may contain Clopidogrel 75 mg or Simvastatin 10 mg. Read the full text of the recall.
1/2018 Obstetrical Needs Assessment (OBNA) form submission
Please submit the obstetrical needs assessment form (OBNA) electronically via Optum OB Care or EPIC. Provider offices without capability for EPIC submission should use Optum OB Care. Faxed copies will not be accepted.

2017 Announcements

9/2017 Recall: All liquid products manufactured by PharmaTechLLC
As a precautionary measure, the distribution firms Leader Brand, Major Pharmaceuticals, and Rugby Laboratories are jointly issuing a nationwide voluntary recall of all lots within expiry of all liquid products manufactured by PharmaTechLLC at its FDA registered facility in Davie, FL, due to possible product contamination. Read the full text of the recall.
9/2017 Recall: Vancomycin Hydrochloride for Injection, USP, 750 mg/vial
Vancomycin Hydrochloride for Injection is manufactured by Hospira. The company recalled one lot number of the medication for safety reasons. This recall is because of the presence of particulate matter. Read the full text of the recall.
9/2017 Recall: Lorazepam Oral Concentrate, USP 2 mg/ml
Lorazepam Oral Concentrate, USP 2mg/ml is being recalled for safety reasons. The dropper may have dose markings in reverse number order, no dose markings, or dose markings that are shifted. Read the full text of the recall.
9/2017 Recall: Pravastatin 40 mg tablet
Pravastatin 40 mg tablets are being recalled for safety reasons. The product may also be labeled as Pravastatin SodiumTablets USP 40 mg but contains Bupropion Hydrochloride XL 300 mg tablets. Read the full text of the recall.
8/2017 Prescription Drug Misuse and Addiction Resources
Like you, we’re here for our community. UPMC Health Plan is hosting an event to discuss and share resources that help your patients and their families cope with a prescription drug problem. Stay educated about the prescription drug epidemic. Learn more about the event.
6/2017 Recall: Eliquis (apixaban) 5 mg tablet
Eliquis (apixaban) 5 mg tablets are being recalled as a precautionary measure from a customer complaint that a bottle labeled as Eliquis 5 mg was found to contain Eliquis 2.5 mg tablets. Read the full text of the recall.
6/2017 Recall: Mibelas 24 Fe Chewable Tablets
Mibelas 24 Fe Chewable Tablets are being recalled for safety reasons because these tablets may be out of sequence and missing expiry/lot information. Read the full text of the recall.
4/2017 Recall: EpiPen and EpiPen Jr Auto-Injectors (epinephrine injection)
EpiPen® and EpiPen® Jr Auto-Injectors are being recalled for safety reasons because these devices may contain a defective part that may result in the devices’ failure to activate. Read the full text of the recall with a list of lot numbers.

2014 Announcements

7/2014 Not all preventive screenings are EHBs
Under the Affordable Care Act, certain preventive services, known as Essential Health Benefits (EHB), are covered at 100 percent. However, not all preventive screenings are EHBs. A screening may be preventive and medically necessary, but if it is not on the list of EHBs, your patient may have a cost share. For a complete list of all preventive services covered at 100 percent, visit www.healthcare.gov/what-are-my-preventive-care-benefits/#part=1/. If there are any questions, you can call Provider Services at 1-866-918-1595 for clarification. Or members can call a Health Care Concierge at the number listed on the back of their card.